Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Anal Squamous Cell Carcinoma: early-phase trial registry

4 of 6 indexed Anal Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Anal Squamous Cell Carcinoma: 6 US clinical trials tracked, 4 recruiting.

Anal Squamous Cell Carcinoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is AIDS Malignancy Consortium, running 1 of these trials.

Enrollment posture brief

Registry condition anal-squamous-cell-carcinoma

OPEN 4 | RECR 67% | LATE 0 | EARLY 5 | RANK #2866 | SPON 1

Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)

Anal Squamous Cell Carci (th…67%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near Anal Squamous Cell Carcinoma

Anal Squamous Cell Carcinoma lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Anal Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Anal Squamous Cell Carcinoma is recruiting above its size-band peers.

    4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Anal Squamous Cell Carcinoma research.

    AIDS Malignancy Consortium accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Anal Squamous Cell Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 80 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Anal Squamous Cell Carcinoma research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3

Named interventions

Most-linked intervention names on Anal Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Capecitabine Drug
2 trials
Prexasertib Drug
1 trials
Mitomycin-C Drug
1 trials
Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery Radiation
1 trials
EVOLVE104 Drug
1 trials
Radiotherapy - High risk group Radiation
1 trials
Radiotherapy - Intermediate risk group Radiation
1 trials
Radiotherapy - Standard risk group Radiation
1 trials

US sites by state

Facility locations filed on Anal Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.

New York 4 trials
Pennsylvania 3 trials
California 3 trials
Texas 2 trials
Tennessee 2 trials
Georgia 2 trials
Florida 2 trials
Wisconsin 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Anal Squamous Cell Carcinoma page

6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anal Squamous Cell Carcinoma condition card totals 6 registered trials; most-linked intervention Capecitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.